Skip to main content

Table 3 Detection limits of the Discovery assay

From: Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients

Cytokine

Samples within standard curvea

Cytokine

Samples within standard curvea

Cytokine

Samples within standard curvea

BCA-1

47/47 (100%)

IL-6

43/47 (91%)

MCP-3

20/47 (43%)

CTACK

47/47 (100%)

IL-7

26/47 (55%)

MCP-4

46/47 (98%)

EGF

38/47 (81%)

IL-8

39/47 (83%)

MDC

47/47 (100%)

ENA-78

47/47 (100%)

IL-9

47/47 (100%)

MIP-1α

34/47 (72%)

Eotaxin-1

47/47 (100%)

IL-10

42/47 (89%)

MIP-1β

44/47 (94%)

Eotaxin-2

45/47 (96%)

IL-12P40

27/47 (57%)

MIP-1d

47/47 (100%)

Eotaxin-3

47/47 (100%)

IL-12P70

41/47 (87%)

PDGF-AA

47/47 (100%)

FGF-2

47/47 (100%)

IL-13

22/47 (47%)

PDGF-BB

46/47 (98%)

Flt-3 Ligand

20/47 (43%)

IL-15

46/47 (98%)

RANTES

37/47 (79%)

Fractalkine

42/47 (89%)

IL-16

47/47 (100%)

sCD40L

47/47 (100%)

G-CSF

40/47 (85%)

IL-17A

39/47 (83%)

SCF

20/47 (43%)

GM-CSF

40/47 (85%)

IL-18

43/47 (91%)

SDF-1

46/47 (98%)

GRO pan

45/47 (96%)

IL-20

45/47 (96%)

TARC

47/47 (100%)

IFNα2

42/47 (89%)

IL-21

22/47 (47%)

TGF-a

36/47 (77%)

IFNγ

36/47 (77%)

IL-23

45/47 (96%)

TNFα

47/47 (100%)

IL-1α

46/47 (98%)

IL-28A

46/47 (98%)

TNFβ

22/47 (47%)

IL-1B

35/47 (74%)

IL-33

29/47 (62%)

TPO

39/47 (83%)

IL-1RA

40/47 (85%)

IP-10

47/47 (100%)

TRAIL

47/47 (100%)

IL-2

28/47 (60%)

I-309

47/47 (100%)

TSLP

42/47 (89%)

IL-3

47/47 (100%)

LIF

33/47 (70%)

VEGF-A

32/47 (68%)

IL-4

19/47 (40%)

MCP-1

47/47 (100%)

6CKINE

47/47 (100%)

IL-5

36/47 (77%)

MCP-2

47/47 (100%)

  
  1. aPercentage of the 47 plasma samples with target protein fluorescence intensity values within the protein standard curve. Absolute cytokine concentration for 15/65 cytokines (shown in bold) could not be calculated in more than 75% of plasma samples because fluorescence intensity values were below the standard curve